Did you know that top cancer centers across the United States work together to improve cancer care? This alliance of leading cancer centers is called the National Comprehensive Cancer Network® (NCCN®).

Cancer care is always changing. NCCN develops evidence-based cancer care recommendations used by health care providers worldwide. These frequently updated recommendations are the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines for Patients plainly explain these expert recommendations for people with cancer and caregivers.


View the NCCN Guidelines for Patients free online
NCCN.org/patientguidelines

Find an NCCN Cancer Center near you
NCCN.org/cancercenters

Connect with us  
Facebook  
Twitter  
Instagram  
YouTube  
LinkedIn
Supporters

NCCN Guidelines for Patients are supported by funding from the NCCN Foundation®

NCCN independently adapts, updates, and hosts the NCCN Guidelines for Patients. Our corporate supporters do not participate in the development of the NCCN Guidelines for Patients and are not responsible for the content and recommendations contained therein.

Additional support is provided by

Ovarian Cancer Research Alliance is committed to curing ovarian cancer, advocating for patients, and supporting survivors. OCRA is the largest ovarian cancer charity with over $122 million invested in research. Our national conference, webinars, and website offer the most up to date information on diagnosis, treatment and living with ovarian and gynecologic cancers. Our support programs include our Patient Support line, peer mentor program, Staying Connected support series, and online community. OCRA builds community through advocacy, research, collaboration, and support. For more information, please visit ocrahope.org or call 212-268-1002.

To make a gift or learn more, visit online or email

NCCNFoundation.org/donate  PatientGuidelines@NCCN.org
Contents

4 Cervical cancer basics
10 Testing and staging
31 Types of treatment
41 Treatment for common types
54 Treatment for neuroendocrine carcinoma of the cervix
58 Survivorship
65 Making treatment decisions
73 Words to know
76 NCCN Contributors
77 NCCN Cancer Centers
80 Index
1 Cervical cancer basics

5 The cervix
7 Cervical changes
8 Risk factors
9 Types of cervical cancer
9 Key points
Cervical cancer basics » The cervix

Cervical cancer is a common cancer of the female reproductive system. Most cervical cancers are caused by long-term infection with human papillomavirus (HPV). HPV is the most common sexually transmitted infection. The use of Pap smears has resulted in much lower rates of cervical cancer in the United States.

The cervix

The cervix is the narrow, lower end of the uterus. The uterus is where a baby grows and develops before being born. During birth, the cervix opens (dilates) and thins (effaces) to allow the baby to move into the vagina. The vagina, or birth canal, is the muscular passage through which babies are born.

An ovary and a fallopian tube are on each side of the upper uterus. The fallopian tubes connect to the top part of the uterus. The ovaries make eggs for sexual reproduction. They also make hormones that affect breast growth, body shape, and the menstrual cycle. Eggs pass out of the ovary and travel through the attached fallopian tube into the uterus. The cervix, uterus, vagina, ovaries, and fallopian tubes are part of the female reproductive system.

The female reproductive system

The reproductive system is a group of organs that work together for the purpose of sexual reproduction. In addition to the uterus (and cervix), this system includes the ovaries, fallopian tubes, and vagina.
Most cervical cancers start in the thin layer of tissue that lines the outer part and inner parts of the cervix.

The ectocervix is the outer part of the cervix. It appears rounded and extends into the vagina. The ectocervix can be seen during an examination of the vagina and cervix using a tool called a speculum. It is lined with cells called squamous cells. In the center of the ectocervix is a narrow opening called the external os. During menstruation, the external os opens slightly to allow blood to pass into the vagina.

The endocervix (endocervical canal) is the inner part of the cervix that forms a canal between the vagina and the body of the uterus. The endocervix is lined with columnar (glandular) cells that make mucus. The inner os is the upper part of the endocervix that serves as an opening between the uterus and the cervix.

The area where the endocervix and ectocervix meet is called the squamo-columnar junction or the transformation zone. Most cervical cancers and pre-cancers start in the ectocervix portion of the transformation zone.

The cervical stroma is the thick layer of muscular tissue beneath the cervical lining. The parametrium is the fat and connective tissue that surrounds the uterus (and cervix) and connects it to the pelvis.

Although the cervix is part of the uterus, uterine cancer is diagnosed and treated differently than cervical cancer. This patient guide does not discuss treatment of uterine cancers, such as endometrial cancer and uterine sarcomas.

**The cervix**

Most cervical cancers start in the area where the inner and outer cervix meet, called the squamo-columnar junction. Specifically, most form in squamous cells that line the ectocervix part of the squamo-columnar junction.
Cervical changes

Cervical cancer starts as areas of abnormal, microscopic cells on the surface of the cervix. These changes are known as cervical dysplasia or cervical intraepithelial neoplasia (CIN). Mutations (changes) in the DNA of these cells cause them to become abnormal. If left untreated, cervical dysplasia may become cervical cancer.

CIN is graded based on the depth of the abnormal cells on the lining of the cervix. The possible grades are 1, 2, or 3. Cervical dysplasia becomes cancer when the abnormal cells invade the muscular tissue beneath the cervical lining (the cervical stroma).

An area of dysplasia or cancer is also referred to as a lesion. Low-grade squamous intraepithelial lesion (LSIL) refers to mild dysplasia (CIN 1). High-grade squamous intraepithelial lesion (HSIL) refers to moderate or severe dysplasia (CIN 2 and 3). HSIL is considered a pre-cancer.
Cervical cancer basics » Risk factors

Risk factors

A risk factor is something that increases the risk of developing a disease. Some people with no known risk factors may develop cervical cancer, while others with risk factors may not.

**HPV infection**

Almost all cervical cancers are caused by long-term infection with human papillomavirus (HPV). HPV is an extremely common sexually transmitted infection (STI). Most sexually active people have or had HPV at one point. Most are unaware that they are or were infected.

In most people, the immune system gets rid of (“clears”) HPV from the body. In other people, the virus causes long-term cell changes that develop into cancer. The progression to cancer often occurs decades after the initial infection.

Experts are still learning why one person gets cervical cancer and another does not. Other types of cancer caused by HPV include anal, head and neck, penile, vaginal, and vulvar cancers.

There are more than 100 types (strains) of HPV. Infection with some strains is more likely to lead to cancer. High-risk forms include HPV-16 and HPV-18. Other HPV types can cause abnormal skin growths, called warts, to form on the anus, genitals, or other areas of the body.

A vaccine that protects against 9 different strains of HPV, including the highest-risk strains, is available in the United States. While previously only recommended for routine use in adolescents and young adults, vaccination is now an option for adults aged 45 and under.

There are two other HPV vaccines available in other parts of the world. One protects against HPV-16 and HPV-18 only. The other targets these and two additional types.

The vaccine works best in younger people (ideally under age 13) because they are less likely to have been exposed to HPV. And, while the vaccine can prevent new HPV infections, it does not treat existing HPV infections or HPV-related cancer.

**Other risk factors**

Other risk factors for cervical cancer are listed below. Some of these lead to a higher risk because they either increase the risk of being exposed to HPV or they weaken the immune system, which can make it harder for the body to clear HPV infection.

- A history of smoking
- Having given birth more than once (called “high parity” or multiparity)
- Oral contraceptive (birth control) use
- Being sexually active at an early age
- A high number of sexual partners
- A history of sexually transmitted infection
- Certain autoimmune diseases
- A weakened immune system due to human immunodeficiency virus (HIV) or AIDS, for example
Types of cervical cancer

Most cervical cancers start in the ectocervix. The ectocervix is lined with squamous cells. Cancer that forms in squamous cells is called a squamous cell carcinoma.

About 2 out of 10 cervical cancers form in the endocervical canal. The endocervix is lined with cells that make mucus. These cells are referred to as glandular, gland-like, secretory, or columnar cells. Cancers that form in glandular cells are called adenocarcinomas.

Less commonly, the cancer may contain both squamous and adenocarcinoma cells. These cancers are referred to as adenosquamous carcinomas. They are sometimes called “mixed” tumors.

Treatment for squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma is the focus of Part 4.

The rarest and most aggressive type of cervical cancer is neuroendocrine carcinoma of the cervix (NECC). Treatment for small cell NECC is the focus of Part 5.

This patient guide does not discuss other types of cervical cancer such as glassy-cell carcinomas, sarcomas, or other tumor types.

Key points

The cervix

- The cervix is the lower part of the uterus that connects to the vagina.
- The ectocervix is the outer part that extends into the vagina. The endocervix is the canal between the vagina and the body of the uterus.
- Most cervical cancers and pre-cancers start in the ectocervix portion of the transformation zone.

Cervical changes

- Cervical cancer starts as areas of abnormal, microscopic cells on the surface of the cervix.
- These changes are known as cervical dysplasia or cervical intraepithelial neoplasia (CIN).

Risk factors

- The risk factor most strongly linked with cervical cancer is long-term infection with HPV, a common sexually transmitted infection.
- A vaccine that protects against 9 different strains of HPV, including the highest-risk strains, is available in the United States.

Types of cervical cancer

- Squamous cell carcinoma is the most common type, followed by adenocarcinoma. Adenosquamous carcinomas are less common.
- Neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive type of cervical cancer.
2 Testing and staging

11 Biopsy
13 Health history and physical exam
13 Blood tests
14 Imaging
16 Fertility and pregnancy
17 Other testing and care
18 Staging
28 Cancer care plan
30 Key points
Your doctors will make a treatment plan just for you. First, they will need to gather information about the cancer and your general health. This chapter describes testing and other care needed to create your treatment plan.

Biopsy

Cervical biopsy and pathologic review

A cervical biopsy involves removing small samples of tissue from the cervix. It is the most commonly used procedure to diagnose cervical cancer. Samples may be taken from the rounded, bottom part of the cervix (ectocervix) and/or from the endocervical canal.

The removed tissue is examined by a specialized doctor called a pathologist. A pathologist is a doctor who specializes in evaluating cells and tissues to diagnose disease. The pathologist looks for abnormal areas, including areas of cancer or pre-cancer. The pathologist also determines the type of cervical cancer, when possible.

Cervical biopsy

A cervical biopsy is the most commonly used procedure to diagnose cervical cancer. A small sample of tissue is removed from the ectocervix and/or the endocervix.
Cone biopsy

Cone biopsy can be both a test and a treatment. It may be used to gather more information about the extent of the cancer after a cervical biopsy. It is also a recommended treatment option for some early cervical cancers.

Also known as cervical conization, cone biopsy involves removing a cone-shaped portion of the cervix. The cone-shaped sample includes tissue from both the ectocervix and the endocervical canal. All of the transformation zone—where the ectocervix and endocervix meet—is removed. Most cervical cancers start in this area.

Most commonly, a technique called cold knife conization (CKC) is used. In this method a surgical scalpel is used to remove the tissue. In some cases loop electrosurgical excision procedure (LEEP) may be performed instead. In LEEP, a thin loop of electrified (heated) wire is used instead of a scalpel to cut out the cervical tissue.

After removing the cone-shaped sample of tissue, your doctor may use a spoon-shaped tool called a curette to scrape a sample of tissue from the cervical canal. This is called endocervical curettage.

The tissue removed during a cone biopsy is examined under a microscope by a pathologist.
Health history and physical exam

To help plan treatment, expect your doctor to ask about your past and current health, including:

- Illnesses, diseases, and surgeries
- Medicines that you take (prescription or over-the-counter)
- Your lifestyle (your diet, activity level, whether you smoke or drink alcohol)
- Possible symptoms of cervical cancer, such as watery vaginal discharge

Your doctor will also do a physical exam of your body, which may include:

- Checking your vital signs (blood pressure, heart rate, breathing rate, and body temperature) and overall appearance
- Feeling and/or listening to the organs in your abdomen, including your liver and stomach
- A pelvic examination to check the size, position, and appearance of your cervix and uterus

It is important to let your doctor know if you have trouble with pelvic exams due to pain, anxiety, or other reasons.

Blood tests

The following blood tests may be ordered as part of initial testing. They can provide helpful information about your general health and the health of your liver, kidneys, and other organs before treatment.

**A complete blood count (CBC)** is a common test that measures the number of red blood cells, white blood cells, and platelets in a sample of blood. Red blood cells carry oxygen throughout the body. White blood cells fight infection. Platelets help to control bleeding.

**A blood chemistry profile** measures the levels of different chemicals in your blood. Chemicals in your blood are affected by your kidneys, bones, and other organs and tissues. Blood chemistry levels that are too high or too low may be a sign that an organ is not working well. Abnormal levels may also be caused by the spread of cancer or by other diseases.

**Liver function tests** are often done along with a blood chemistry profile. The liver is an organ that does many important jobs, such as remove toxins from the blood. Liver function tests measure enzymes that are made or processed by the liver. Levels that are too high or too low may be a sign of liver damage or cancer spread.

If you have not had a recent human immunodeficiency virus (HIV) test, or have never been tested, your doctor may recommend it. If you have HIV, you are likely to be referred to an HIV specialist. Having HIV should not affect your cancer treatment. The treatment options described in this guide apply to both HIV-positive and HIV-negative patients.
Imaging

Imaging helps determine the extent of the cancer. The size and spread of the cancer is used to guide treatment.

Computed tomography

You may have a computed tomography (CT) scan of your chest, abdomen, and/or pelvis. A CT scan is a more detailed kind of x-ray. It takes many pictures of an area inside the body from different angles.

A computer combines the pictures to make three-dimensional (3-D) images. During the scan, you will lie face up on a table that moves through a large tunnel-like machine. To see everything better, a substance called contrast may be injected into your vein and also mixed with a liquid you drink. Contrast makes the CT pictures clearer. The contrast may cause you to feel flushed or get hives. You will be able to hear and talk to the technician at all times. You may hear buzzing or clicking during the scan.

PET/CT

A CT scan may be combined with another imaging test called positron emission tomography (PET). PET uses small amounts of radioactive materials called radiotracers. About an hour before the scan, you will be injected with a sugar radiotracer. The radiotracer gives off a small amount of energy that can be seen by the imaging machine. Cancer appears brighter in the pictures because cancer cells use sugar more quickly than normal cells. In some cases, PET may be performed with magnetic resonance imaging (MRI) (described next) instead of CT.

MRI

An MRI makes pictures of areas inside the body without using radiation. An MRI can show the tissues of the uterus, cervix, and vagina in detail.
Magnetic resonance imaging

MRI uses strong magnetic fields and radio waves to make pictures of areas inside the body. It is especially good at making clear pictures of areas of soft tissue. Unlike a CT scan or x-ray, MRI does not use radiation.

You may have an MRI of your pelvis. An MRI can show the tissues of the uterus, cervix, and vagina closely. An MRI may show whether the cancer has spread to tissues next to the cervix, such as the parametrium, vagina, bladder, or rectum.

For those with small cell neuroendocrine carcinoma of the cervix (NECC), MRI of the brain is also recommended as part of initial testing.

Getting an MRI scan is similar to getting a CT scan. You will lie face-up on a table that moves through a large tunnel in the scanning machine. The scan may cause your body to feel a bit warm. Like a CT scan, a contrast agent will be used to make the pictures clearer. MRI scans take longer to complete than CT scans. The full exam can take an hour or more. Tell your doctor if you get nervous in tight spaces.

Transvaginal ultrasound

If you cannot have MRI of your pelvis, you may have an ultrasound instead. Ultrasound uses sound waves to make pictures of areas inside of the body. It is good at showing the size, shape, and location of the cervix.

In a transvaginal ultrasound, a probe will be inserted into your vagina. This helps your doctor see the cervix and nearby areas more clearly.
**Fertility and pregnancy**

If you want the option of becoming pregnant in the future, talk to your care team about fertility-sparing treatment. It is typically only an option for small, early-stage cancers. Recommendations for fertility-sparing treatment are provided in *Part 4: Treatment for common types*.

If fertility preservation is desired, talk to your doctor about seeing a reproductive endocrinologist. Reproductive endocrinologists are doctors that specialize in fertility. Although natural pregnancy will not be possible, options to discuss may include ovarian transposition, egg or embryo freezing, and consideration of possible surrogate pregnancy in the future.

**Ovarian transposition**

Cervical cancer treatment may involve external beam radiation therapy (EBRT). Radiation damages the ovaries and causes them to stop producing hormones needed for natural pregnancy. Ovarian transposition is a surgery that moves one or both ovaries out of the range of the radiation beam. The medical name for this procedure is oophoropexy.

Ovarian transposition before starting EBRT may be an option if you are premenopausal and have the most common type of cervical cancer, squamous cell carcinoma.

---

**Egg freezing**

Unfertilized eggs can be removed, frozen, and stored for later use. The medical term for this is oocyte preservation.

**Surrogacy**

If you have frozen embryos or frozen eggs (oocytes), you may consider using a surrogate. A surrogate (often a relative or friend) volunteers to have the embryos inserted into their uterus. They carry the pregnancy and give birth.

For more information on fertility preservation, see the *NCCN Guidelines for Patients: Adolescent and Young Adult Cancer* at NCCN.org/patientguidelines and on the NCCN Patient Guides for Cancer app.
Other testing and care

Checking the bladder and bowel

Your doctor may want to examine nearby organs, like the bladder and bowel, for signs of cancer. If these tests are needed, expect to receive general anesthesia. This means you will be fully sedated and unaware that the procedure is taking place. These are referred to as examinations under anesthesia (EUAs).

Cystoscopy is a procedure to see inside the bladder and other organs of the urinary tract. It is performed using a hollow tool with a magnifying lens at one end, called a cystoscope. The cystoscope is inserted through the urethra and guided into the bladder.

Proctoscopy is a procedure to see inside the anus and rectum. It is performed with a thin, tube-like instrument with a light and magnifying lens called a proctoscope.

If abnormal or suspicious areas are seen during cystoscopy or proctoscopy, tissue samples will be removed and tested (biopsied).

If you smoke or vape, seek help to quit

If you smoke or vape, it’s important to quit. Smoking can limit how well cancer treatment works. Smoking and vaping can also increase the risk of lung problems during and after chemotherapy. They also increase your chances of developing other cancers.

Nicotine is the chemical in tobacco that makes you want to keep smoking. Nicotine withdrawal is challenging for most people who smoke. The stress of having cancer may make it even harder to quit. If you smoke, ask your care team about resources and programs that can help you quit.

For online support, try these websites:

- SmokeFree.gov
- BeTobaccoFree.gov
- CDC.gov/tobacco
Staging

The results of imaging and the other testing just described are used to determine the stage (extent) of the cancer. Your treatment options will depend on the cancer stage.

The International Federation of Gynecology and Obstetrics (FIGO) system is used to stage cervical cancer. There are four main stages in the FIGO system: I (1), II (2), III (3), and IV (4). The stages are broken down into sub-stages that have letters and may also have a number.

The following information is used to stage the cancer in the FIGO system:

- The size or extent/depth of the tumor
- Whether any lymph nodes have cancer
- Whether the cancer has spread to involve nearby organs such as the bladder or rectum
- Whether the cancer has spread to distant organs such as the liver, lungs, and/or bone (metastasized)

The stages are explained and pictured on the following pages. In general, people with earlier cancer stages have better outcomes, but not always. Some people will do better than expected for their stage, and some will do worse.
Stage 1A cervical cancer

The cancer is 5 millimeters (mm) or smaller. 5 mm is about the size of a standard pencil eraser. Cancers 3 mm or smaller are stage 1A1. Cancers between 3 and 5 mm are stage 1A2.
Stage 1B1 cervical cancer

The cancer is larger than 5 mm but smaller than 2 cm.
Stage 1B2 and 1B3 cervical cancer

The cancer is only in the cervix. In stage 1B2, the cancer is between 2 and 4 cm. In stage 1B3, the cancer is larger than 4 cm.
Stage 2 cervical cancer

The cancer has grown beyond the cervix. If the cancer has grown into the upper vagina, the stage is 2A. Stage 2A1 cancers are 4 cm or smaller. Stage 2A2 cancers are larger than 4 cm. Stage 2B cancer has grown into the parametrium. The parametrium is the fat and connective tissue that surrounds the cervix and uterus.
Stage 3A cervical cancer

The cancer has grown into the lower third of the vagina.
Stage 3B cervical cancer

The cancer has grown into the pelvic wall and/or has caused kidney swelling or dysfunction.
Stage 3C cervical cancer

There is cancer in lymph nodes near the cervix (pelvic lymph nodes) and/or in lymph nodes in the abdomen, called the para-aortic lymph nodes.
Stage 4A cervical cancer

The cancer has spread to nearby organs, such as the bladder or rectum.
Stage 4B cervical cancer

The cancer is metastatic. It has spread to the liver, lungs, abdomen, bone, or other distant sites or lymph nodes.
Cancer care plan

Your treatment team
Treatment for cervical cancer often involves a team of experts, including a gynecologic oncologist, a medical oncologist, and a radiation oncologist.

A gynecologic oncologist is an expert in surgery and chemotherapy for female reproductive cancers. A medical oncologist is an expert in treating cancer with chemotherapy. A radiation oncologist is an expert in the use of radiation therapy to treat cancer.

Your primary care physician (PCP) and gynecologist can also be a part of your team. These health care providers can help you express your feelings about your care to the team. Treatment of other health problems may be improved if they are aware of and involved in your cancer care. In addition to doctors, you may receive care from nurses, social workers, and other health experts. Ask to have the names and contact information of your health care providers included in the treatment plan.

Cancer treatment
There isn't a treatment plan that is best for everyone. There is often more than one treatment option, including clinical trials. Clinical trials study the safety and effectiveness of investigational treatments.

The treatment that you and your doctors agree on should be described in the treatment plan. All known side effects should also be noted. It is also important to note the goal of treatment and the chance of a good treatment outcome.

Keep in mind that your treatment plan may change. Testing may provide new information.

How well the treatment is working may change the plan. Or you may change your mind about treatment. Any of these changes may require a new treatment plan.

Stress and symptom control
Anxiety and depression are common in people with cancer. At your cancer center, cancer navigators, social workers, and others can help. Help may include support groups, talk therapy, exercising, spending time with loved ones, or medication.

You may be unemployed or miss work during treatment. Or, you may have little or no health insurance. Talk to your treatment team about work, insurance, or money concerns. They will include information in the treatment plan to help you manage the costs of care.

For more information, see the NCCN Guidelines for Patients: Distress During Cancer Care at NCCN.org/patientguidelines and on the NCCN Patient Guides for Cancer app for more information.
Supportive care

Supportive care aims to relieve the symptoms of cancer or the side effects of cancer treatment. It can help relieve discomfort and improve quality of life. Supportive care may be given alone or with cancer treatment.

Side effects

Managing side effects is a shared effort between you and your care team. It is important to speak up about bothersome side effects, such as nausea and vomiting. Ask about your options for managing or relieving the effects of treatment.

More information on nausea and vomiting is available at NCCN.org/patientguidelines and on the NCCN Patient Guides for Cancer app.
Key points

- Cervical cancer is most often diagnosed by cervical biopsy. Samples of cervical tissue are removed and tested for dysplasia and cancer.
- A cone biopsy may be used to gather more information after a cervical biopsy or to treat early cervical cancer. It involves removing a cone-shaped portion of the cervix.
- Blood tests provide helpful information about your general health and the health of your liver, kidneys, and other organs before treatment.
- Imaging helps determine the extent of the cancer before treatment. Initial imaging may include CT, MRI, PET, and/or transvaginal ultrasound.
- A cystoscopy and/or proctoscopy under anesthesia may be needed to look for signs of cancer in the bladder and bowel.
- Fertility-sparing treatment may be an option for cancer that is only in the cervix.
- The stage is a rating of the extent of the cancer before any treatment is given. It is used to determine your treatment options.
- The FIGO system is used to stage cervical cancer.
- Quitting smoking can lead to better cancer treatment outcomes. Help is available if you are ready to stop smoking.
3

Types of treatment

32 Surgery
34 External beam radiation therapy
35 Chemoradiation
36 Brachytherapy
37 Systemic therapy
38 Clinical trials
40 Key points
In this chapter, the main treatments for cervical cancer are described. Your treatment options will depend on the extent of the cancer and other factors.

Surgery

Surgery is often the main treatment for early-stage cervical cancer. The types of surgery that may be used are described below.

Removing only a portion of the cervix may be an option for the earliest stage of cervical cancer. In most cases, however, the entire cervix must be removed. While this can sometimes be performed through the vagina, an abdominal incision (cut) is usually needed. When the surgery is performed through a traditional (big) incision through the abdomen, the approach is known as laparotomy.

Minimally invasive (also called laparoscopic) surgery involves making only a few small cuts into your body. There is usually less pain and scarring compared to surgery that uses a larger cut through the abdomen. The time it takes to recover is also usually shorter.

Cone biopsy

Cone biopsy involves removing a cone-shaped section of the cervix that includes tissue from both the ectocervix and endocervix. It is a recommended treatment option for some small cervical cancers. See Part 2: Testing and staging for more information on cone biopsy.

Trachelectomy

Trachelectomy is surgery to remove the cervix. The upper part of the vagina and pelvic lymph nodes may also be removed. Trachelectomy is a fertility-sparing surgery. The uterus and ovaries are left intact, allowing for the possibility of natural pregnancy in the future.

In a simple trachelectomy, only the cervix is removed. In a radical trachelectomy, about 2 centimeters (less than a half inch) of vaginal tissue is removed in addition to the cervix. Both types can be performed either through the vagina or the abdomen.

Hysterectomy

Hysterectomy is surgery to remove the uterus (including the cervix). The types of hysterectomy that may be used to treat cervical cancer are described below.

An extrafascial (simple) hysterectomy removes only the uterus (including the cervix). Extrafascial hysterectomy can be performed through the vagina, through the abdomen, or using a minimally invasive approach. This type is most commonly used for stage IA1 cancer.

A modified radical hysterectomy removes the uterus (including the cervix), a portion of the connective tissue that holds the cervix in place, and about a half inch or less of the vagina. Modified radical hysterectomy is performed through the abdomen.

A radical hysterectomy removes the uterus (including the cervix), much of the connective tissue that holds the cervix in place, and the top quarter or third of the vagina. Radical hysterectomy is performed through the abdomen.

There are other differences between these hysterectomy types. If surgery is planned,
your surgeon will explain the procedure recommended for you in detail.

**Ovary preservation**
The ovaries may or may not be removed during hysterectomy. If you have not entered menopause, surgery that removes both ovaries will cause menopause. This is referred to as surgical menopause. It is caused by the sudden drop in estrogen in the body. There are short- and long-term symptoms and risks of surgical menopause that can greatly affect quality of life. When caused by surgery, the symptoms of menopause may be sudden and more severe.

Symptoms include hot flashes, sleeping problems, night sweats, weight gain, and changes in mood. Vaginal atrophy is another common symptom. Vaginal atrophy is a condition in which the lining of the vagina becomes thin, dry, and inflamed. Long-term risks of not having enough estrogen include cardiovascular disease and bone loss (osteoporosis).

If hysterectomy is being considered, ask your doctor if keeping your ovaries is appropriate.

**Lymph node dissection**
Cancer cells can travel through blood and lymph. Lymph is a clear fluid that carries infection-fighting white blood cells. Lymph nodes are bean-shaped glands found throughout the body. They contain immune cells that help the body fight infection and disease.

During surgery for cervical cancer, lymph nodes may be removed in order to be tested for cancer. This is called lymph node dissection or lymphadenectomy. In order to identify and remove the lymph node(s) most likely to contain cancer, a **sentinel lymph node biopsy** may be performed. This involves injecting a special dye or a radioactive substance into the cervix near the cancer. Lymph nodes containing the dye or substance can be seen using a special camera. These are the sentinel nodes. They are removed and tested for cancer.

Testing the removed nodes helps determine the extent (spread) of the cancer. Removing lymph nodes can also help limit the spread of cancer cells through lymph. The closest lymph nodes to the cervix are the pelvic nodes.

Cervical cancer generally spreads to these nodes first. Lymph nodes in the abdomen, called the para-aortic nodes, are also sometimes removed.

**Pre-treatment surgical staging**
If the cancer has spread beyond the cervix, a hysterectomy is not performed but pelvic and/or para-aortic lymph nodes may be removed and tested before any treatment is given.

Knowing whether pelvic or para-aortic nodes contain cancer can help guide treatment decisions for more advanced cancers. A minimally invasive approach is typically used to access and remove the lymph nodes. This is referred to as laparoscopic surgical staging.
Types of treatment  » External beam radiation therapy

External beam radiation therapy

Radiation therapy uses high-energy waves similar to x-rays to kill cancer cells. In external beam radiation therapy (EBRT), a large machine aims radiation at the cancer site. The radiation passes through skin and other tissue to reach the tumor and nearby lymph nodes. EBRT is given in small doses, called fractions.

An advanced type of EBRT called intensity-modulated radiation therapy (IMRT) is often used to treat cervical cancer. IMRT uses many small beams of different strengths. This allows a high dose of radiation to reach the tumor while limiting the amount of radiation to the surrounding normal tissue. With IMRT it is possible to reduce radiation to important nearby organs and structures, such as the bowel, bladder, external genitalia, and hip joints. This can help reduce treatment-related side effects.

Stereotactic body radiation therapy (SBRT) is a highly specialized type of EBRT used to treat metastatic cervical cancer. High doses of radiation are delivered to tumors in the liver, lungs, or bone using very precise beams. Treatment is typically delivered in 5 or fewer sessions.

Side effects

Common side effects during the 5 to 6 weeks of EBRT include fatigue, skin redness and irritation, diarrhea, nausea, and frequent or painful urination. Most of these side effects develop gradually. They increase during treatment and gradually decrease once treatment is over.

When the ovaries are included in the radiation field, it causes premature (early) menopause. The symptoms are similar to those caused by surgical menopause, as described above. Ovarian transposition is a surgery that moves one or both ovaries out of the range of the

External beam radiation therapy

A large machine aims radiation at the tumor, passing through skin and other tissue to reach it.
radiation beam. This procedure may be an option if you are premenopausal and have the most common type of cervical cancer, squamous cell carcinoma.

Otherwise, your doctor may consider the use of menopausal hormone therapy (MHT) after radiation therapy has completed. This approach used to be called hormone replacement therapy or HRT. Hormone therapy for menopause helps lessen some of the side effects of radiation-induced menopause. See Part 6: Survivorship for more information.

Radiation therapy for cervical cancer can also have long-term and serious side effects on fertility, sexual health, and bowel and bladder function.

**What to expect**

A planning session, called simulation, is needed before EBRT begins. You will first be placed in the treatment position. You will be asked to lie on your back and stay very still. You may get fitted for a prop to help you stay still during the radiation sessions.

Pictures of the cancer site(s) will be obtained with a CT scan. Using the CT images and sophisticated computer software, your radiation oncologist will make a treatment plan. The plan will specify the radiation dose(s) and the number of sessions you will need. There will be several days between the time of simulation and the beginning of your treatment sessions. This allows sufficient time for careful treatment planning, dose calculation, and quality assurance.

During treatment, you will lie on a table as you did for simulation. Devices may be used to keep you from moving. This helps to target the tumor. Ink marks (tattoos) on your skin will help position your body accurately for daily treatments. The technician will be operating the machine from an adjacent room. You will be able to see, hear, and speak with them at all times. You will not see, hear, or feel the radiation. One session can take less than 10 minutes.

**Chemoradiation**

EBRT and chemotherapy are often used together to treat cervical cancer. They are given concurrently (during the same time period) in a treatment strategy called chemoradiation. Chemoradiation is recommended for most locally advanced cervical cancers. These cancers have grown beyond the cervix but have not spread to the liver, lungs, or bones.

As part of chemoradiation, there are typically 5 EBRT treatment sessions per week for 5 to 6 weeks. Chemotherapy is typically given once weekly during this time. See page 37 for more information on chemotherapy.
Brachytherapy

Also known as internal radiation therapy, brachytherapy involves treatment with radioactive material placed inside the body. Brachytherapy allows a high dose of radiation to be targeted at the tumor while limiting the amount delivered to surrounding normal tissue.

During brachytherapy, instruments are placed into the cervix, uterus, and vagina. A radioactive material then travels into the instruments that have been placed in the body. This method is known as intracavitary brachytherapy. Sometimes, additional instruments (catheters, or thin hollow tubes) are placed in the tumor itself or in tissues next to the tumor (interstitial brachytherapy). For the treatment of cervical cancer, intracavitary brachytherapy is most often used. Interstitial brachytherapy is a specialized technique that is used for more advanced cancers that involve the parametrium. It is best performed at cancer centers with experience in this method.

Brachytherapy for cervical cancer may be given in short bursts, called high dose-rate (HDR) brachytherapy, or in long bursts, called low dose-rate (LDR) brachytherapy. Most centers currently use HDR brachytherapy. Treatment is typically given in 3 to 5 sessions over 2 weeks.

If you have not had a hysterectomy, a device called an applicator is inserted into the uterus through the vagina. A “tandem and ring” applicator is commonly used for HDR brachytherapy. The tandem is a long, thin tube that extends into the uterus. The ring is a hollow circle that stays in the vagina, pressed against the cervix. A tandem and ovoid applicator uses hollow, rounded capsules instead of a ring. General anesthesia or deep sedation is often required, especially for the first applicator placement.

The applicator is placed to align with the tissue targeted for treatment. Often, an imaging technique (MRI or CT) is used to guide placement of the applicator. These images are used to design the brachytherapy treatment plan. The applicator is connected to a brachytherapy machine. A radiation source travels from the machine through the hollow tubes and into the applicator. Treatment takes about 10 minutes.

Sometimes brachytherapy is given as treatments over a couple days. In this case, the instruments are placed and left in the body until all the treatments have been given (1 to 2 days). You will need to remain in bed until treatment is complete so that the instruments don’t move.

Brachytherapy is typically started in the final week or right after completing EBRT. Shrinking the tumor with EBRT first allows for better placement of the brachytherapy applicators. Treatment with both types of radiation therapy can be completed within 7 to 8 weeks.

Side effects

The side effects of brachytherapy are similar to those of EBRT and include:

- Skin irritation near treatment area
- Tiredness (fatigue)
- Soreness in your pelvic area
- Difficulty urinating or painful urination
- Softer bowel movements or diarrhea
- Increased vaginal discharge
Systemic therapy

Systemic therapy is treatment with substances that travel in the bloodstream, reaching cells throughout the body. Chemotherapy, targeted therapy, and immunotherapy are types of systemic therapy.

Most systemic therapies are given intravenously. This means they are slowly infused into your bloodstream through a vein. Infusions are often given in cycles of treatment days followed by days of rest. This allows your body to recover between cycles.

Chemotherapy

Platinum-based chemotherapy is the most commonly used systemic therapy for cervical cancer. It stops the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Cisplatin is generally preferred for platinum-based chemotherapy. If cisplatin is expected to be too harsh or cannot be given for other reasons, a different platinum drug called carboplatin may be used instead.

As part of treatment with chemoradiation, cisplatin is typically given on a 7-day cycle (once weekly) for 5 to 6 weeks. When used for recurrent or metastatic cancer, infusions are typically given once every 3 weeks.

Targeted therapy and immunotherapy

Targeted therapy and immunotherapy are newer types of systemic therapy. Unlike chemotherapy, targeted therapy and immunotherapy are most effective at treating cancers with specific features, called biomarkers. They may be options for treating cervical cancer that returns or spreads after treatment with chemotherapy.

Side effects of systemic therapy

Systemic therapy can kill healthy cells in addition to cancer cells. The damage to healthy cells causes potentially harsh side effects. The side effects of chemotherapy depend on many factors, including the drug(s), the dose, and the person. In general, side effects are caused by the death of fast-growing cells, which are found in the intestines, mouth, and blood. As a result, common side effects include:

- Loss of appetite
- Nausea
- Vomiting
- Mouth sores
- Hair loss
- Fatigue
- Increased risk of infection
- Bleeding or bruising easily
- Nerve damage (neuropathy)

Cisplatin can damage the kidneys. People whose kidneys do not work well may not be able to have cisplatin. An alternative chemotherapy drug may be used. Cisplatin can also cause ringing in the ears (tinnitus) or hearing problems or loss.

Ask your treatment team for a list of common and rare side effects of each systemic therapy you are receiving. There are ways to prevent or alleviate some of these effects.
Clinical trials

A clinical trial is a type of medical research study. After being developed and tested in a laboratory, potential new ways of fighting cancer need to be studied in people. If found to be safe and effective in a clinical trial, a drug, device, or treatment approach may be approved by the U.S. Food and Drug Administration (FDA).

Everyone with cancer should carefully consider all of the treatment options available for their cancer type, including standard treatments and clinical trials. Talk to your doctor about whether a clinical trial may make sense for you.

Phases

Most cancer clinical trials focus on treatment. Treatment trials are done in phases.

- **Phase 1** trials study the dose, safety, and side effects of an investigational drug or treatment approach. They also look for early signs that the drug or approach is helpful.

- **Phase 2** trials study how well the drug or approach works against a specific type of cancer.

- **Phase 3** trials test the drug or approach against a standard treatment. If the results are good, it may be approved by the FDA.

- **Phase 4** trials study the long-term safety and benefit of an FDA-approved treatment.

Who can enroll?

Every clinical trial has rules for joining, called eligibility criteria. The rules may be about age, cancer type and stage, treatment history, or general health. These requirements ensure that participants are alike in specific ways and that the trial is as safe as possible for the participants.

Informed consent

Clinical trials are managed by a group of experts called a research team. The research team will review the study with you in detail, including its purpose and the risks and benefits of joining. All of this information is also provided in an informed consent form. Read the form carefully and ask questions before signing it. Take time to discuss it with family, friends, or others you trust. Keep in mind that you can leave and seek treatment outside of the clinical trial at any time.

Start the conversation

Don’t wait for your doctor to bring up clinical trials. Start the conversation and learn about all of your treatment options. If you find a study that you may be eligible for, ask your treatment team if you meet the requirements. If you have already started standard treatment, you may not be eligible for certain clinical trials. Try not to be discouraged if you cannot join. New clinical trials are always becoming available.

Frequently asked questions

There are many myths and misconceptions surrounding clinical trials. The possible benefits and risks are not well understood by many with cancer.

Will I get a placebo?

Placebos (inactive versions of real medicines) are almost never used alone in cancer clinical trials. It is common to receive either a placebo with a standard treatment or a new drug with a standard treatment. You will be informed,
verbally and in writing, if a placebo is part of a clinical trial before you enroll.

**Are clinical trials free?**
There is no fee to enroll in a clinical trial. The study sponsor pays for research-related costs, including the study drug. You may, however, have costs indirectly related to the trial, such as the cost of transportation or child care due to extra appointments. During the trial, you will continue to receive standard cancer care. This care is billed to—and often covered by—insurance. You are responsible for copays and any costs for this care that are not covered by your insurance.

### Finding a clinical trial

**In the United States**
NCCN Cancer Centers
NCCN.org/cancercenters

The National Cancer Institute (NCI)
cancer.gov/about-cancer/treatment/
clinical-trials/search

**Worldwide**
The U.S. National Library of Medicine (NLM)
clinicaltrials.gov

**Need help finding a clinical trial?**
NCI's Cancer Information Service (CIS)
1.800.4.CANCER (1.800.422.6237)
cancer.gov/contact
Key points

**Surgery**
- Hysterectomy is surgery that removes the uterus, including the cervix. Some of the vagina and cervical connective tissue may also be removed.
- The ovaries may be removed or left in place during hysterectomy. Removing them causes surgical (premature) menopause.
- Trachelectomy is surgery that removes the cervix. It is a type of fertility-sparing surgery. The upper part of the vagina may also be removed.

**Radiation therapy**
- Radiation therapy uses high-energy x-rays to kill cancer cells. In EBRT, a large machine aims radiation at the cancer site.
- Brachytherapy involves treatment with radioactive material placed inside the body. It delivers a high dose of radiation directly to the tumor.

**Systemic therapy**
- Platinum-based chemotherapy is the most commonly used systemic therapy for cervical cancer.
- Targeted therapy and immunotherapy are most often used for recurrent and/or metastatic cervical cancer with specific biomarkers.

**Chemoradiation**
- EBRT and platinum-based chemotherapy given concurrently (during the same time period) is a treatment strategy called chemoradiation.

**Clinical trials**
- Clinical trials give people access to investigational treatments that may, in time, be approved by the FDA.
4

Treatment for common types

42 Fertility-sparing treatment
44 Early-stage cancer
46 Locally advanced cancer
47 Surveillance
48 Recurrence
50 Metastatic cancer
53 Key points
This chapter presents recommended treatment options for the most common types of cervical cancer. Surgery is usually recommended for early-stage cancers, while most locally advanced cancers are treated with chemoradiation.

This section applies to the following types of cervical cancer:

- Squamous cell carcinoma
- Adenocarcinoma
- Adenosquamous carcinoma

Treatment is based on the cancer stage. The stage describes how far the cancer has likely spread based on imaging and other testing.

A risk factor that guides treatment for cervical cancer is lymphovascular space invasion (LVSI). LVSI means that there are tumor cells in the blood vessels or lymph vessels inside the tumor. Cancers with LVSI are more likely to spread to nearby lymph nodes. Nearby lymph nodes are more likely to be removed.

Fertility-sparing treatment

Surgical treatment for early-stage cervical cancer often involves surgery that removes the uterus (hysterectomy). Carrying a pregnancy is not possible after a hysterectomy. If the cancer has not spread beyond the cervix (stage 1), fertility-sparing treatment may be an option, if desired. This approach involves surgery that does not remove the uterus or ovaries, allowing you the option of natural pregnancy in the future.

If fertility-sparing treatment is being considered, ask your doctor about getting the opinion of a reproductive endocrinologist. Reproductive endocrinologists are doctors that specialize in fertility. A fertility-sparing approach is not appropriate for some uncommon types of cervical cancer.

**Stage 1A1**

Cone biopsy is recommended for stage 1A1 cancers **without known LVSI**. If the results are good, no further treatment is needed. If the results suggest that the cancer was not completely removed, you may have another cone biopsy. Or, your doctor may recommend radical trachelectomy.

For stage 1A1 cancers **with LVSI**, treatment with either cone biopsy or radical trachelectomy is recommended. Pelvic lymph node evaluation should also be performed. *If trachelectomy is planned, see the next page for information on treatment after surgery.*

**Stage 1A2**

Cone biopsy is an option for some very-low-risk stage 1A2 cancers. The tumor must be smaller than 2 centimeters, there must be no LVSI, and other criteria must be met. Pelvic lymph node evaluation is performed in addition to the cone biopsy.

For stage 1A2 cancers **with LVSI**, treatment with either cone biopsy or radical trachelectomy is recommended. Pelvic lymph node evaluation is also performed. *If trachelectomy is planned, see the next page for information on treatment after surgery.*
Treatment for common types  » Fertility-sparing treatment

**Stage 1B1**

Cone biopsy is an option for some very-low-risk stage 1B1 cancers. The tumor must be smaller than 2 cm, there must be no LVSI, and other criteria must be met. Pelvic lymph node evaluation is also performed.

For stage 1B1 cancers that do not meet the criteria for cone biopsy, radical trachelectomy with pelvic lymph node evaluation is recommended. Lymph nodes in the abdomen (para-aortic nodes) may be removed in addition to pelvic lymph nodes.

**Stage 1B2**

Fertility-sparing surgery is not performed often for stage 1B2 cancers. Because most research on fertility-sparing surgery applies to smaller tumors, abdominal surgery is generally preferred.

**Treatment after surgery**

**If testing finds no cancer** in tissue beyond the cervix or in lymph nodes removed during surgery, there are 2 options. External beam radiation therapy (EBRT) is recommended for cancers with risk factors. Observation is recommended for cancers without risk factors. Your doctor will consider the tumor size, whether there is LVSI, and other factors when determining if EBRT is a good choice for you.

If EBRT is planned, platinum chemotherapy may be given during the same time period. This is called chemoradiation.

**If cancer is found** in any pelvic or para-aortic lymph nodes, or in any tissues outside the cervix, treatment with chemoradiation is recommended. Vaginal brachytherapy may be given in addition to EBRT and platinum chemotherapy.

---

**Fertility-sparing treatment**

Fertility-sparing treatment may be an option, if desired, for some stage 1 cancers. This approach involves surgery that does not remove the uterus or ovaries, allowing you the option of natural pregnancy in the future.
Early-stage cancer

The treatment options in this section apply to:

- Cancers that are only in the cervix (stage 1)
- Cancers that have spread to the upper vagina (stage 2A)

Surgery is recommended for most early-stage cancers. Treatment with EBRT alone or with chemoradiation may be recommended after surgery.

If you cannot have surgery, radiation therapy is usually given instead.
Treatment with both external (EBRT) and internal (brachytherapy) is recommended.

Options for non–fertility-sparing treatment are provided next according to stage. EBRT or chemoradiation may be needed after surgery.

Stage 1A1

Stage 1A1 cancers are typically diagnosed by cone biopsy. If cancer is found at the margins (edges) of the removed tissue and there is no LVSI, you may or may not have more treatment. If you want the option of becoming pregnant in the future, the cancer can often be observed without treatment. For those who do not want to preserve fertility, an extrafascial (simple) hysterectomy is usually recommended. Surveillance will begin.

If cancer or pre-cancer is found in the cone biopsy margins and surgery is not possible, brachytherapy is recommended. EBRT may be given in addition to brachytherapy.

If cancer or pre-cancer is found in the cone biopsy margins and surgery is possible, there are two possibilities. Your doctor may recommend another cone biopsy to confirm that the cancer is actually stage 1A1. If pre-cancer is found at the margins, either an extrafascial (simple) hysterectomy or a modified radical hysterectomy is recommended. Lymph nodes in the pelvis may be removed during either type of hysterectomy.

For stage 1A1 cancers with LVSI, modified radical hysterectomy with lymph node evaluation is recommended.

Stage 1A2 and 1B1

Extrafascial hysterectomy with lymph node evaluation is recommended for low-risk stage 1B1 and 1A2 cancers. These cancers must meet the following criteria for extrafascial hysterectomy to be considered:

- No LVSI
- No cancer found in cone biopsy margins
- The tumor is any grade squamous cell carcinoma or a low-grade adenocarcinoma
- The tumor is 2 cm or smaller and not very deep
- No signs of cancer spread in the body

For 1A2 and 1B1 cancers that do not meet the above criteria, radical hysterectomy with pelvic lymph node evaluation is recommended. Lymph nodes in the abdomen (para-aortic nodes) may be removed in addition to pelvic lymph nodes.
Stage 1B2 and 2A1

Radical hysterectomy with pelvic lymph node evaluation is recommended for these stages. Lymph nodes in the abdomen (para-aortic nodes) may be removed in addition to pelvic lymph nodes.

Stage 1B3 and 2A2

Stage 1B3 cancers are larger than 4 cm (about the size of a walnut) but do not extend beyond the cervix. Stage 2A2 cancers are also larger than 4 cm and extend into the upper vagina.

These cancers may be treated as early-stage (with surgery) or as locally advanced (with chemoradiation and brachytherapy). At this time, treatment with chemoradiation is preferred. See the next page for more information on this option.

If surgery is planned, radical hysterectomy and pelvic lymph node dissection is recommended. Lymph nodes in the abdomen (para-aortic nodes) may also be removed.

Treatment after surgery

After surgery, the pathologic (surgical) stage of the cancer is determined by examining the removed tissue. The following information applies to the stages below, as determined by surgery:

- Stage 1
- Stage 2A

If testing finds no cancer in tissue beyond the cervix or in lymph nodes removed during surgery, there are 2 options. External beam radiation therapy (EBRT) is recommended for cancers with risk factors. Observation is recommended for cancers without risk factors. Your doctor will consider the tumor size, whether there is LVSI, and other factors when determining if EBRT is a good choice for you.

If EBRT is planned, platinum chemotherapy may be given during the same time period. This is called chemoradiation.

If cancer is found in any pelvic or para-aortic lymph nodes, or in any tissues outside the cervix, treatment with chemoradiation is recommended. Vaginal brachytherapy may be given in addition to EBRT and platinum chemotherapy.
Locally advanced cancer

This section describes treatment options for cervical cancer that has grown beyond the cervix but has not spread to the liver, lungs, or bones. Cancers that are close to spreading beyond the cervix (stage 1B3) are also considered locally advanced. Locally advanced cancers are not metastatic.

The information in this section applies to the following stages:

- Stage 1B3 and 2A2
- Stage 2B
- Stage 3
- Stage 4A

Locally advanced cancers are more likely to have spread to lymph nodes than early-stage cancers. Knowing whether lymph nodes in the pelvis or abdomen contain cancer can help guide treatment with EBRT for these cancers. You may have extra imaging to look for lymph nodes with cancer.

Another approach is to surgically remove and test lymph nodes before any treatment is given. A minimally invasive method is typically used to access and remove the lymph nodes. This is called surgical staging. If surgical staging is performed, the para-aortic lymph nodes are typically removed. Pelvic lymph nodes may or may not be removed.

Treatment with all of the following is recommended for most locally advanced cervical cancers:

- Chemoradiation (EBRT and platinum chemotherapy)
- Brachytherapy

If cancer is found in pelvic lymph nodes, EBRT will include the pelvis. If any para-aortic nodes are known or suspected to have cancer, EBRT will be given to a larger treatment area that includes these nodes as well.

While treatment as described above is currently preferred for stage 1B3 and 2A2 cancers, surgery is sometimes recommended.

Let us know what you think!

Please take a moment to complete an online survey about the NCCN Guidelines for Patients.

NCCN.org/patients/response
Surveillance

After finishing treatment, you will have testing to look for early signs of possible recurrence. This is known as surveillance. The information that follows applies to surveillance for common types of cervical cancer and for small cell neuroendocrine carcinoma of the cervix (NECC).

Physical exams

Physical exams performed by your oncologist are an important part of surveillance, especially in the first 5 years after treatment. At these follow-up visits, tell your doctor about any changes in your health. Such changes include new or worsening symptoms and other health conditions or concerns.

The recommended time frames for these follow-up visits are as follows:

**Years 1 and 2:** Every 3 to 6 months  
**Years 3, 4, and 5:** Every 6 to 12 months  
**After year 5:** Once a year or as agreed upon with your doctor

Time frame ranges are used to allow for differences in individual risk of recurrence and in patient and provider preference. Those considered at higher risk of recurrence may benefit from more frequent exams than those with a lower risk.

After the fifth year, visits are generally spaced out to once per year. Or you and your doctor may agree on a different schedule after discussing your personal risk of recurrence.

Imaging

Unlike physical exams, imaging is generally not needed at regular intervals for an extended time after treatment. Imaging is typically ordered if you have new or worsening symptoms, or if other findings suggest recurrence or spread. Follow-up imaging is described below according to the cancer stage.

**Stage 1**

If you had radiation or chemoradiation after non–fertility-sparing treatment, or if the cancer is stage 1B3, you may have a fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (FDG-PET/CT) scan 3 to 6 months after finishing treatment. The area from the neck to the mid-thigh is typically scanned.

After fertility-sparing treatment, you may have an MRI of your pelvis (with contrast) 6 months after surgery and then yearly for 2 to 3 years.

**Stages 2, 3, and 4A**

Imaging is recommended 3 to 6 months after treatment for stage 2, 3, and 4A cervical cancers. An FDG-PET/CT scan is preferred, but a CT with contrast is also a recommended option. The area from the neck to the mid-thigh will be scanned.

Other imaging for these stages may include a pelvic MRI with contrast 3 to 6 months after finishing treatment.

**Metastatic cancer**

For stage 4B or distant recurrences of cervical cancer, imaging is used mainly to learn how the cancer is responding to systemic therapy. Imaging may include CT, MRI, and/or PET/CT.
Pap tests

Depending on the type of surgery you have (if any), you may have annual Pap screening tests after treatment. Pap testing is helpful for finding new areas of abnormal and/or precancerous cells. It is not as good at detecting recurrent cervical cancer. Pap testing is also known as cervical or vaginal cytology.

Blood tests

If you have symptoms, or a physical exam was suspicious for recurrence, your doctor may order blood tests.

In addition to a complete blood count (CBC), testing may measure blood urea nitrogen (BUN) and creatinine levels. These check your kidney function. Liver function tests may also be ordered.

Survivorship

In addition to surveillance testing, a range of other care is important for cancer survivors. This includes keeping alert for symptoms of cancer recurrence. See Part 6: Survivorship for more information.

Recurrence

This section discusses cervical cancer that does not improve with treatment (persistent) or that returns after treatment (recurrent). If your doctor suspects recurrence based on your symptoms or a physical exam, you will have imaging tests to check. This could include CT, PET, and/or MRI.

Surgery to look inside the body (exploratory surgery) may be helpful in some cases. The goal is to learn the extent of the cancer. This can help guide treatment decisions.

Biomarker testing

Biomarkers are features of a cancer that can help guide treatment. Biomarkers are often mutations (changes) in particular genes. They can also be proteins that are made in response to the cancer.

Biomarker testing is recommended for all recurrent cervical cancers. The results help determine whether treatment with certain targeted therapies is an option. The results can also be used to determine whether you can join certain clinical trials. Some doctors order biomarker testing early in the course of treatment. Many doctors wait and order it only if the cancer returns or spreads.

Testing should be performed on tumor tissue removed during a biopsy or surgery when possible. Otherwise, a sample of blood may be tested instead. Other names for this testing include molecular testing, tumor profiling, genomic testing, tumor gene testing, next-generation sequencing (NGS), mutation testing, and comprehensive genomic profiling (CGP).

**Testing for PD-L1 expression** is recommended for everyone with recurrent, progressive, or metastatic cervical cancer. If
the PD-L1 level exceeds a set cutoff point, the cancer is considered PD-L1-positive. If needed, treatment with certain targeted therapies or immunotherapies may be an option for PD-L1–positive tumors.

The biomarkers listed below are less common in cervical cancer but should still be tested for.

- Mismatch repair (MMR)
- Microsatellite instability (MSI)
- Tumor mutational burden (TMB)
- NTRK gene fusion (for those with a cervical sarcoma)
- HER2
- RET gene fusion

**If cancer returns to the pelvis**

Cervical cancer that returns to the pelvis only is known as a local or regional recurrence. If the area has not been treated with radiation and the cancer can be surgically removed, this is generally preferred. After surgery, EBRT and systemic therapy are recommended. Brachytherapy may also be given.

If the area has already been treated with radiation and it is no longer an option, possible treatment options are listed below. The best option(s) for you will depend on the specific location of the new cancer growth in the pelvis.

- Pelvic exenteration surgery
- Radical hysterectomy
- Brachytherapy
- Individualized EBRT and possibly systemic therapy
- Systemic therapy
- Resection of new cancer growth

Radical hysterectomy and brachytherapy are typically only considered in carefully selected patients. Supportive care is always an option, whether you are in active treatment or not.

**Pelvic exenteration**

Pelvic exenteration is a radical surgery that involves removing multiple organs from the pelvis. The goal is to cure the cancer by removing all of the organs to which cancer has or may spread.

All remaining organs of the female reproductive system are removed during pelvic exenteration. This includes the uterus, fallopian tubes, ovaries, and vagina. Nearby organs in the pelvis including the bladder, rectum, and/or anus may also be removed.

If the bladder and/or organs involved in bowel function are removed, a diversion is typically performed. Diversions are surgical procedures that divert (redirect) urine and/or stool to new openings through which they exit the body.

**Vaginal reconstruction**

It is often possible to reconstruct the vagina after pelvic exenteration. A surgeon can create an artificial vagina using muscle from another area of your body. A muscle in the lower abdomen called the rectus abdominus is often used for vaginal reconstruction. This procedure is sometimes referred to as muscle flap reconstruction.

**If the bladder is removed**

An ileal (incontinent) conduit is one type of urinary diversion. After the bladder is removed, your surgeon will create a new tube from a piece of intestine (ileum). This tube will allow your kidneys to drain. Your urine will now exit the body through a small opening called a stoma. A small disposable bag attached to the outside of your abdomen collects the urine.
This is called an ostomy bag or ostomy pouch. The bag stays attached to your body with the help of an adhesive part called a “wafer.” The wafer sticks to the skin and acts as a watertight barrier.

Another way urine may be redirected after removing the bladder is a continent urinary diversion. It is also referred to as an artificial bladder or “Indiana pouch.” This method uses a segment of intestine to create a pouch to hold urine. The pouch has a channel for urine to pass through made from intestine that connects it to the wall of the abdomen.

A stoma is made in the abdominal wall at the location of the reservoir. Sometimes the stoma can be made in the belly button, making it less noticeable. To drain urine, a catheter is inserted into the reservoir several times a day. A benefit to this type of urinary diversion is that an ostomy bag does not need to be worn on the outside of the body.

If the rectum is removed
If the rectum is removed, a permanent colostomy may be created. A colostomy connects the remaining colon to the outside of the abdomen. Stool exits the body through a stoma and goes into a bag attached to the skin. In some cases, the remaining colon can be connected to the remaining rectum or anus and a permanent colostomy may not be required. You may retain near-normal bowel function. If the anus is removed during the surgery, a permanent colostomy is always needed.

If both the bowel and bladder are removed
If both urinary and fecal diversion are needed, a double-barreled wet colostomy (DBWC) is sometimes used. In this technique, only one opening (stoma) on the surface of the abdomen is needed. Urine and stool are kept separate until they exit the body through the same stoma. Compared to having separate urinary and fecal diversions, DBWC has been found to have other benefits, such as fewer leaks.

Metastatic cancer

If left untreated, or if not diagnosed early, cervical cancer often spreads to the liver, lungs, and/or bone. Cervical cancer that has spread to these organs is metastatic. Cancer that had already metastasized when it was found is stage 4B. If cancer returns and metastasizes after treatment, it is known as a distant recurrence. The information in this section applies to both types of metastatic disease.

Metastatic cervical cancer is very hard to cure. Treatment is usually with systemic therapy. The goal is to keep the cancer under control and prevent further spread. If the tumor has not already been tested for biomarkers, it may be tested now. Biomarker testing can help determine whether you may be eligible for certain targeted therapies or immunotherapies.

It may be possible to remove or destroy the new cancer growth(s) using one or more of the treatments listed below.

- Resection (surgery)
- EBRT
- Ablative therapies

Ablative therapies destroy cancerous lesions with little harm to nearby tissue. They are often delivered using a specially designed needle (a probe or electrode) placed directly into or next to the tumor.
Stereotactic body radiation therapy (SBRT) is a highly specialized type of EBRT that may be used to treat tumors in the liver, lungs, or bone. Only a few treatment sessions are needed.

If treatment with the local therapies listed above is complete, systemic therapy may follow.

**Systemic therapy**

Metastatic cervical cancer is usually treated with platinum-based chemotherapy. If you had prior treatment with cisplatin, it may not work as well again on its own. In this case, it is often given with 1 or 2 other medicines, as part of a combination regimen.

A factor your doctor will consider when selecting a systemic therapy regimen to use first (as “first-line” therapy) is whether the cancer has the PD-L1 biomarker. At this time, preferred first-line regimens for **PD-L1–positive** cancers are listed below. Bevacizumab (Avastin) might be added to either regimen.

- Pembrolizumab (Keytruda) + cisplatin + paclitaxel
- Pembrolizumab (Keytruda) + carboplatin + paclitaxel

The preferred first-line regimen for all other metastatic cervical cancers is:

- Cisplatin + paclitaxel + bevacizumab

Pembrolizumab is an immune checkpoint inhibitor (a type of immunotherapy). Bevacizumab is a type of targeted therapy called a biologic that is designed to work with chemotherapy.

Other recommended first-line regimens include different combinations of cisplatin (or carboplatin), topotecan, paclitaxel, and/or bevacizumab.

**Second-line or beyond**

If you cannot have more platinum-based chemotherapy, there are other options. Treatment with pembrolizumab (Keytruda) is preferred for cancers with one of the following biomarkers:

- TMB-H
- PD-L1–positive
- MSI-H/dMMR

For cancers with a biomarker other than those listed above, immunotherapy or targeted therapy may be an option. Biomarkers and their related systemic therapies are listed in **Guide 1**.

For cancers without any of the biomarkers in **Guide 1**, preferred options include:

- Tisotumab vedotin-tftv (Tivdak), and
- Cemiplimab (Libtayo).

If immunotherapy is planned, see the *NCCN Guidelines for Patients for Immunotherapy Side Effects: Immune Checkpoint Inhibitors* at [NCCN.org/patientguidelines](https://nccn.org/patientguidelines) and on the *NCCN Patient Guides for Cancer* app.
Supportive care

Supportive care is available to everyone with metastatic cervical cancer, regardless of whether you are in active treatment. Supportive care refers to a range of care and resources often needed by patients with metastatic cancer. Hospice care, access to pain specialists, and emotional and spiritual support are all components of supportive care. Because metastatic cancer cannot be cured, the main goal of supportive care is to make you more comfortable and to help keep the cancer under control. Supportive care may also help you live longer and feel better overall. When used for advanced cancers, supportive care is often called palliative care.

You may also consider enrolling in a clinical trial. Ask your treatment team if there is an open clinical trial that you can join.

Advance care planning

Talking with your doctor about your prognosis can help with treatment planning. If the cancer cannot be controlled or cured, a care plan for the end of life can be made. There are many benefits to advance care planning, including:

- Knowing what to expect
- Making the most of your time
- Lowering the stress of caregivers
- Having your wishes followed
- Having a better quality of life

Guide 1

Biomarkers and their related treatments

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Targeted therapy or immunotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD-L1 positive</td>
<td>• Pembrolizumab (Keytruda)</td>
</tr>
<tr>
<td></td>
<td>• Nivolumab (Opdivo)</td>
</tr>
<tr>
<td>MSI-H/dMMR</td>
<td>Pembrolizumab (Keytruda)</td>
</tr>
<tr>
<td>TMB-H</td>
<td>Pembrolizumab (Keytruda)</td>
</tr>
<tr>
<td>HER2-positive</td>
<td>Fam-trastuzumab deruxtecan-nxki (Enhertu)</td>
</tr>
<tr>
<td>RET gene fusion-positive</td>
<td>Selpercatinib (Retevmo)</td>
</tr>
<tr>
<td>NTRK gene fusion-positive</td>
<td>• Larotrectinib (Vitrakvi)</td>
</tr>
<tr>
<td></td>
<td>• Entrectinib (Rozlytrek)</td>
</tr>
</tbody>
</table>
Another part of the planning involves hospice care. Hospice care does not include treatment to fight the cancer but rather to reduce symptoms caused by cancer. Hospice care may be started because you do not wish to continue treatment, because no other cancer treatment is available, or because you are too sick for treatment.

Hospice care allows you to have the best quality of life possible. Care is given all day, every day of the week. You can choose to have hospice care at home or at a hospice center. One study found that patients and caregivers had a better quality of life when hospice care was started early.

An advance directive describes the treatment you’d want if you weren’t able to make your wishes known. It can name a person whom you’d want to make decisions for you. It is a legal paper that your doctors have to follow. It can reveal your wishes about life-sustaining machines, such as feeding tubes. If you already have an advance directive, it may need to be updated to be legally valid.

**Key points**

**Early-stage**
- Treatment for early-stage cervical cancer often involves hysterectomy. EBRT or chemoradiation may follow surgery.
- If you cannot have surgery, EBRT and brachytherapy are recommended.
- Fertility-sparing treatment may be an option for some stage 1 cancers. Treatment typically involves either cone biopsy or radical trachelectomy.

**Locally advanced**
- Extra imaging and/or surgical staging may be done for locally advanced cancers to see if there is cancer in lymph nodes.
- Combined treatment with chemoradiation and brachytherapy is recommended for most locally advanced cervical cancers.

**Surveillance**
- Surveillance after treatment involves physical exams and staying alert for symptoms of recurrence or spread.
- Follow-up imaging is recommended 3 to 6 months after finishing treatment for stage 2, 3, or 4A cancer.
- Imaging is generally only ordered if you have symptoms or there are other possible signs of relapse.

**Recurrence**
- If you haven’t had treatment with EBRT, it is likely to be used to treat cancer that returns to the pelvis.
- Pelvic exenteration surgery may be used to treat recurrent cancer in the pelvis that cannot be treated with radiation therapy.

**Metastatic cancer**
- Platinum-based chemotherapy is recommended to treat metastatic cancer when possible. For cancers with biomarkers, targeted therapy or immunotherapy may be an option.
- It may be possible to remove or destroy new cancer growth using resection, EBRT, and/or ablative treatments.
- Supportive care is available to everyone with cervical cancer.
5

Treatment for neuroendocrine carcinoma of the cervix

55 Early-stage NECC
56 Locally advanced NECC
57 Key points
Early-stage NECC

For cancers that have not spread beyond the cervix, treatment is guided by the size of the tumor.

**Tumors 4 cm or smaller**

If you are a candidate for surgery, radical hysterectomy and pelvic lymph node dissection are recommended for tumors 4 cm or smaller. Para-aortic lymph nodes may or may not be removed for testing. Treatment with either chemotherapy alone or chemoradiation (chemotherapy and EBRT) follows surgery.

A second option for tumors 4 cm or smaller is treatment with chemoradiation (chemotherapy and EBRT) and brachytherapy. When treatment is over, your doctor may recommend additional systemic therapy.

**Tumors larger than 4 cm**

One option for tumors 4 cm or larger is treatment with chemoradiation and brachytherapy first. More chemotherapy may follow.

Another possibility is that chemotherapy will be given first to try to shrink the cancer. If chemotherapy works well, surgery (radical hysterectomy) may be performed. If you have this surgery, treatment with EBRT alone or chemoradiation may be given next. More chemotherapy may follow.

If radical hysterectomy is not performed, treatment with chemoradiation (EBRT and chemotherapy) and brachytherapy is the next step. More chemotherapy may follow.
Locally advanced NECC

The term "locally advanced" is used to describe cervical cancer that has grown beyond the uterus but has not spread to the liver, lungs, or bone. This includes stage 2, 3, and 4A cancers. Cancers that are close to spreading beyond the uterus (stage 1B3) are also considered locally advanced. Locally advanced cancers are non-metastatic.

At this time, treatment with chemoradiation and brachytherapy is preferred for locally advanced NECC. When these treatments are over, you may have more chemotherapy with the same regimen.

The other recommended strategy is treatment with chemotherapy first, followed by chemoradiation and brachytherapy.

After initial treatment

If initial treatment works well, surveillance will begin. Surveillance involves testing to look for early signs of recurrence. The surveillance strategy for more common types of cervical cancer is also recommended for NECC. See page 47 for information.

If the cancer does not improve with initial treatment, it is known as “persistent.” Options for treating persistent NECC that is only in the pelvis may include:

- Systemic therapy
- Pelvic exenteration surgery

These are also treatment options for recurrent, non-metastatic NECC.

If the cancer spreads to the liver, lungs, or bone (metastasizes), see “Metastatic cancer” in Part 4: Treatment for common types. Recommendations for treating metastatic cancer apply to common cervical cancers and to NECC.

Supportive care

Supportive care is always an option. This care is available to everyone with persistent, recurrent, or metastatic cancer, regardless of whether you are in active treatment. Supportive care refers to a range of resources offered to patients with advanced or metastatic cancer. Hospice care, access to pain specialists, and emotional and spiritual support are all components of supportive care.

Because the cancer cannot be cured, the main goal of supportive care is to make you more comfortable and to help keep the cancer under control. Supportive care may also help you live longer and feel better overall. When used for advanced cancers, supportive care is often called palliative care.

Consider a clinical trial

Enrolling in a clinical trial allows you to receive treatment while helping researchers learn more about this rare cancer. Ask your care team if you qualify for any current clinical trials. Clinical trials are discussed in more detail at the end of Part 3: Types of treatment.
Key points

- Small cell NECC is a rare and usually aggressive (fast-growing) type of cervical cancer.
- Treatment for NECC often involves chemotherapy, EBRT, and brachytherapy. Surgery (combined with other treatment) may also be an option for early-stage NECC.
- Options for treating persistent NECC that is only in the pelvis include systemic therapy and possibly pelvic exenteration surgery.
- Supportive care is an option for everyone with NECC. Talk to your treatment team about resources available to you.
- There is much to be learned about rare cancers like small cell NECC. Think about enrolling in a clinical trial for treatment.

We want your feedback!

Our goal is to provide helpful and easy-to-understand information on cancer.
Take our survey to let us know what we got right and what we could do better.

NCCN.org/patients/feedback
6 Survivorship

59 Staying alert for recurrence or spread
60 Late and long-term effects
63 Healthy habits
64 Key points
Survivorship focuses on the physical, emotional, and financial issues unique to cancer survivors. Survivorship begins at diagnosis and continues through treatment, recurrence, and end of life. Managing the long-term side effects of having cancer and making healthy choices are important parts of survivorship.

During and after cancer treatment, your primary care physician (PCP), also known as a general practitioner or family doctor, plays an important role in your care. Your oncologist and PCP should work together to make sure you get the follow-up care you need. Ask your oncologist for a written survivorship care plan to be shared with your PCP that includes:

- A summary of your cancer treatment history
- A description of possible short-term, late, and long-term side effects
- Recommendations for monitoring for the return of cancer
- Information on when your care will be transferred to your PCP
- Clear roles and responsibilities for both your cancer care team and your PCP
- Recommendations on your overall health and well-being

**Staying alert for recurrence or spread**

Your cancer treatment team and your primary care doctor will work together to make sure you get recommended follow-up testing. But you have one of the biggest responsibilities—paying close attention to your body. If cervical cancer does come back, it may affect your body in ways that you can feel or notice (symptoms).

Your doctor will teach you about the symptoms that may mean cervical cancer has returned or spread. They include:

- Vaginal discharge or bleeding
- Blood in your urine or stool
- Weight loss
- Loss of appetite
- Pain in the pelvis, hips, back, or legs
- Coughing
- Shortness of breath
- Swelling in your stomach or legs

If you notice any of these symptoms, contact your doctor right away. Do not wait for your next scheduled visit.
Late and long-term effects

Some side effects of cervical cancer treatment can start early and linger longer than expected. Others may not appear until long after treatment is over. Many cervical cancer survivors experience changes in bowel, urinary, and sexual function. More general effects such as fatigue, trouble breathing, and difficulty sleeping (insomnia) are also common.

The extent and degree of symptoms vary widely between patients. Ask your treatment team for a complete list of possible late and long-term side effects.

Bowel and bladder changes

Urinary incontinence (the inability to hold urine in the bladder) and urgency (a sudden, strong need to urinate) are possible after surgery or radiation therapy for cervical cancer. Watery and/or frequent bowel movements (diarrhea) are also possible. Occasional bleeding may occur either with urination or bowel movements. Pelvic floor physical therapy, described next, can help with bowel and bladder changes.

Ostomy care

If you have an ostomy, you want to join an ostomy support group. Another option is to see a health care provider that specializes in ostomy care, such as an ostomy nurse. People with ostomies can still live very active lifestyles. Consider consulting with an ostomy professional before undertaking vigorous physical activity.

Pelvic floor physical therapy

The pelvic floor is a group of muscles that supports the organs of the pelvis. These muscles play a key role in bowel and bladder control as well as sexual function and arousal. There are ways to strengthen these muscles before and after treatment. This is known as pelvic floor physical therapy, and there are health care professionals who specialize in it. Pelvic floor therapy can include at-home exercises to tighten and release the vaginal and anal muscles (Kegel exercises) as well as hands-on techniques by a physical therapist. Ask your treatment team for help finding a pelvic floor specialist in your area.

Infertility and premature menopause

Surgically removing the ovaries or exposing them to radiation causes a sudden drop in estrogen and progesterone. This results in infertility, and possibly also menopausal symptoms. These include stopping of periods, hot flashes, night sweats, weight gain, and mood changes.

The lining of the vagina can become thin, dry, and inflamed. This is called vaginal atrophy. Not having enough estrogen can also have long-term risks, including heart disease and bone loss (osteoporosis).

When these hormonal changes cause symptoms of menopause, menopausal hormone therapy (MHT) may be an option. This can include systemic (oral or intravenous) estrogen (combined with progestins for those with a uterus intact) and vaginal applications of estrogen. Discussion with a specialized menopausal symptom team may be helpful to determine whether this treatment is right for you.

Vaginal moisturizers

Older age, menopause, and some cervical cancer treatments can cause the vagina
to become dry and less stretchy. To offset this side effect, use of water-based vaginal moisturizers is highly encouraged. Like moisturizers for your body, vaginal moisturizers restore moisture to the vagina and help to keep the vaginal tissue healthy. Vaginal moisturizers can be used daily. Many come with applicators to make using them easier. Vaginal estrogen cream or tablets may be particularly helpful where there has been thinning of the vaginal and vulvar tissues due to loss of estrogen.

**Vaginal dilator therapy**

Radiation therapy to the pelvic area can cause the vagina to become shorter and narrower. This is called vaginal stenosis. Vaginal stenosis can make it uncomfortable or even painful to have sex, or to have vaginal examinations by a doctor. Vaginal dilator therapy can be used to lessen the effects of vaginal stenosis. A vaginal dilator is a device used to gradually stretch or widen the vagina.

You can start using a dilator as soon as 2 to 4 weeks after radiation therapy has ended and can continue to use it for as long as you want. Vaginal dilators are not one-size-fits-all. Different sizes are available, as are dilator kits containing different size devices. The size of the dilator can be increased over time as the vagina lengthens and widens.

**Sexual health**

Sexual side effects can occur after cervical cancer treatment, including:

- Reduced sex drive (libido)
- Vaginal dryness
- Pain during sex
- Narrowing and shortening of the vagina (vaginal stenosis)

While it may be uncomfortable to talk about sexual health, keep in mind that these side effects are common and can often be

**Mental wellness**

Expect your care team to ask about your mental health. If they don't, speak up. There are many resources available that can improve mental health and wellness for cancer survivors.
managed or lessened. Consider seeing a sexual health therapist. These health care professionals specialize in helping cancer survivors and others overcome and manage sexual side effects of cancer treatment. Many cancer treatment centers have programs focused solely on sexual health after cancer treatment. Ask your doctor about resources available through your cancer center that can help minimize the impact of cancer treatment on your sexual health.

**Mental health and wellness**

It can be hard to cope with the effects of cancer and its treatment. Many survivors report having a lower quality of life after cancer treatment. Depression, anxiety, fear of recurrence, and trouble adjusting to changes in the body are possible. Many people also have financial stressors, such as concerns or hesitation about returning to work and insurance coverage issues. Personal relationships, sexuality, and intimacy may also be affected by a cancer diagnosis or cancer treatment.

If you are anxious, distressed, depressed, or are just having trouble coping with life after cancer, you are not alone. Tell your treatment team about these symptoms. Expect your treatment team to ask about your mental health. If they don’t, speak up. There are many resources available that can improve mental health and wellness for cancer survivors. Social workers at your treatment center are often excellent resources to help connect you with mental health and financial resources.

**Weakened bones**

Radiation treatment to the pelvis can weaken bones in the pelvis, putting you at increased risk of fractures. Your doctor may want to start monitoring the density of your bones.

**Nerve damage**

Chemotherapy can damage the sensory nerves. This is known as neuropathy. The damage can result in pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It often begins in the hands or feet and gets worse over time. Neuropathic pain is often described as a shooting or burning pain.

**Swelling**

Treatment for cervical cancer often involves removing lymph nodes during surgery. Lymph may not drain properly after lymph nodes are removed. This can result in lymphedema. Lymphedema is swelling caused by a build-up of lymph fluid in tissues. It most often occurs in the lower body for cervical cancer survivors.
Healthy habits

Monitoring for the return of cervical cancer is important after finishing treatment. But it is also important to keep up with other aspects of your health. Steps you can take to help prevent other health issues and to improve your quality of life are described next.

Get screened for other types of cancer, such as breast, skin, and colorectal cancer. Talk to your primary care doctor about recommended cancer screening tests for your age and risk level.

Get other recommended health care such as blood pressure screening and hepatitis C screening, and immunizations (such as the flu shot).

Leading a healthy lifestyle includes maintaining a healthy body weight. Exercising at a moderate intensity for at least 150 minutes per week is recommended. Talk to your doctor before starting a new exercise regimen. Try to eat a healthy diet that includes lots of plant-based foods.

Alcohol may increase the risk of certain cancers. Drink little to no alcohol.

If you smoke, quit! Your doctor can provide (or refer you for) counseling on how to stop smoking.

More information

For more information on cancer survivorship, the following are available at NCCN.org/patientguidelines and on the NCCN Patient Guides for Cancer app:

- Survivorship Care for Healthy Living
- Survivorship Care for Cancer-Related Late and Long-Term Effects

These resources address topics relevant to ovarian cancer survivors, including:

- Anxiety, depression, and distress
- Fatigue
- Pain
- Sexual health
- Sleep problems
- Healthy lifestyles
- Immunizations
- Working, insurance, and disability concerns
Key points

- Survivorship focuses on the physical, emotional, and financial issues unique to cancer survivors.
- Ask your oncologist (cancer doctor) about a survivorship care plan. This document can help your oncologist and PCP coordinate your follow-up care.
- It is important to stay alert for signs of potential recurrence or spread, including vaginal discharge or bleeding, blood in your urine or stool, and weight loss.
- Many cervical cancer survivors experience problems with bowel, urinary, and sexual function.
- Other physical side effects include infertility, early menopause, fatigue, trouble breathing, insomnia, painful nerve damage, and swelling of the legs.
- Pelvic floor physical therapy, hormone replacement therapy, and vaginal moisturizers and dilators can help with some side effects.
- Sexual health therapists specialize in helping cancer survivors and others overcome and manage sexual side effects of cancer treatment.
- Depression, anxiety, fear of recurrence, and trouble adjusting to changes in the body are possible after cervical cancer treatment.
- Talk to your treatment team about resources that can improve mental health and wellness for cancer survivors.
7
Making treatment decisions

66  It’s your choice
66  Questions to ask
71  Resources
It is important to be comfortable with the cancer treatment you choose. This choice starts with having an open and honest conversation with your care team.

It’s your choice

In shared decision-making, you and your care team share information, discuss the options, and agree on a treatment plan. It starts with an open and honest conversation between you and your team.

Treatment decisions are very personal. What is important to you may not be important to someone else.

Some things that may play a role in your decision-making:

› What you want and how that might differ from what others want
› Your religious and spiritual beliefs
› Your feelings about certain treatments
› Your feelings about pain or side effects
› Cost of treatment, travel to treatment centers, and time away from school or work
› Quality of life and length of life
› How active you are and the activities that are important to you

Think about what you want from treatment. Discuss openly the risks and benefits of specific treatments and procedures. Weigh options and share concerns with your doctor. If you take the time to build a relationship with your team, it will help you feel supported when considering options and making treatment decisions.

Second opinion

It is normal to want to start treatment as soon as possible. While cancer should not be ignored, there is time to have another cancer care provider review your test results and suggest a treatment plan. This is called getting a second opinion, and it’s a normal part of cancer care. Even doctors get second opinions!

Things you can do to prepare:

› Check with your insurance company about its rules on second opinions. There may be out-of-pocket costs to see doctors who are not part of your insurance plan.
› Make plans to have copies of all your records sent to the doctor you will see for your second opinion.

Support groups

Many people diagnosed with cancer find support groups to be helpful. Support groups often include people at different stages of treatment. Some people may be newly diagnosed, while others may be finished with treatment. If your hospital or community doesn’t have support groups for people with cancer, check out the websites listed in this book.

Questions to ask

Possible questions to ask your cancer care team are listed on the following pages. Feel free to use these or come up with your own. Be clear about your goals for treatment and find out what to expect from treatment.
Questions about treatment

1. What treatment plan do you recommend for me?
2. What are the risks and benefits of each treatment? What about side effects?
3. Will my age, general health, and other factors affect my treatment options?
4. Would you help me get a second opinion?
5. How soon should I start treatment? How long does treatment take? Is there a clinical trial that I can join?
6. Where will I be treated? Will I have to stay in the hospital or can I go home after each treatment?
7. What can I do to prepare for treatment?
8. What symptoms should I look out for during treatment?
9. How much will the treatment cost? How can I find out how much my insurance company will cover?
10. Are there supportive services that I can get involved in? Support groups?
Questions about recurrence

1. How likely is it that the cancer will return? What is my risk based on?
2. Will I need pelvic exenteration? If so, which organs will be removed?
3. Will I need an ostomy?
4. How likely is the cancer to metastasize? Where does it usually spread?
5. Am I eligible for treatment with a targeted therapy or immunotherapy?
6. What biomarkers does my cancer have?
7. What if the cancer returns a second time?
Questions about clinical trials

1. Is a clinical trial right for me?
2. What is the purpose of the study?
3. How many people will be in the clinical trial?
4. What are the tests and treatments for this study? How often will they take place?
5. Has the drug been used before? Has it been used for other types of cancers?
6. What side effects can I expect? Can the side effects be controlled?
7. How long will I be in the clinical trial?
8. How will you know if the treatment is working?
9. Will I be able to get other treatment if this treatment doesn’t work?
10. Who will help me understand the costs of the clinical trial?
What is your experience?

1. Are you board-certified? If yes, in what area?
2. How many patients like me have you treated?
3. How many procedures like the one you’re suggesting have you done?
4. Is this treatment a major part of your practice?
5. How many of your patients have had complications?
Resources

Cancer Hope Network
cancerhopenetwork.org

Cervivor
cervivor.org

HPV Cancers Alliance
hpvca.org

National Cancer Institute (NCI)
cancer.gov/types/cervical

MSI Insiders
Msiinsiders.org

Ovarian Cancer Research Alliance (OCRA)
Ocrahope.org

Smokefree.gov
smokefree.gov

Triage Cancer
Triagecancer.org

U.S. National Library of Medicine Clinical Trials Database
clinicaltrials.gov

Take our survey, and help make the NCCN Guidelines for Patients better for everyone!
NCCN.org/patients/comments
Words to know

**abdomen**
The belly area between the chest and pelvis.

**adenocarcinoma**
Cervical cancer that starts in glandular cells in the endocervix. About 2 out of 10 cervical cancers are adenocarcinomas.

**adenosquamous carcinoma**
A less common type of cervical cancer that contains both squamous cells and gland-like cells.

**biomarkers**
Specific features of cancer cells. Biomarkers can include proteins made in response to the cancer and changes (mutations) in the DNA of cancer cells.

**brachytherapy**
A type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor. Also called internal radiation therapy.

**cancer grade**
A rating of how abnormal cancer cells look when viewed under a microscope.

**cancer stage**
A rating of the extent of cancer in the body.

**cervical intraepithelial neoplasia (CIN)**
Abnormal and potentially pre-cancerous cells on the surface of the cervix. Also called cervical dysplasia.

**cervix**
The lower part of the uterus that connects to the vagina.

**clinical trial**
A type of research involving people that assesses investigational treatments.

**cone biopsy**
A procedure in which a cone-shaped piece of abnormal tissue is removed from the cervix. May be used to gather more information about the extent of a cancer or to treat some early cervical cancers.

**ectocervix**
The rounded, outer part of the cervix that extends into the vagina. The ectocervix is lined with cells called squamous cells.

**endocervix**
The inner part of the cervix that forms a canal between the vagina and the uterus. The endocervix is lined with columnar (glandular) cells that make mucus.

**external beam radiation therapy (EBRT)**
Treatment with radiation received from a large machine outside the body. Types of EBRT include intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT).

**extrafascial hysterectomy**
Surgery to remove the uterus (including the cervix). The vagina is not removed. The connective tissue and fat surrounding the cervix is not removed. Also called simple hysterectomy.

**fallopian tube**
A thin tube through which an egg travels from the ovary to the uterus.


**gynecologic oncologist**
A surgeon who is an expert in cancers that start in the female reproductive organs.

**human papillomavirus (HPV)**
A common sexually transmitted infection. Almost all cervical cancers are caused by long-term HPV infection.

**infusion**
A method of giving drugs slowly through a needle into a vein.

**lymph**
A clear fluid containing white blood cells that fight infection and disease.

**lymph nodes**
Small groups of disease-fighting cells located throughout the body.

**lymphovascular space invasion (LVSI)**
The presence of tumor cells in the blood vessels or lymph vessels inside the tumor. LVSI is a risk factor for cancer spread.

**medical oncologist**
A doctor who is an expert in treating cancer with systemic therapies, such as chemotherapy.

**menopause**
The point in time when menstrual periods end.

**metastasis**
The spread of cancer cells from the first tumor to another body part.

**modified radical hysterectomy**
Surgery to remove the uterus (including the cervix). A half inch or less of the vagina is also removed. Some of the connective tissue and fat surrounding the cervix is also removed.

**mutation**
A change in the DNA sequence of a cell. Mutations may be inherited, random, or caused by DNA-damaging sources in the environment. Some mutations are biomarkers (features) that may guide cancer treatment.

**neuroendocrine carcinoma of the cervix (NECC)**
A rare and often aggressive subtype of cervical cancer.

**neuropathy**
A nerve problem that causes pain, tingling, and numbness in the hands and feet.

**oophoropexy**
Surgery that moves one or both ovaries out of the range of the radiation beam. Also called ovarian transposition.

**ovary**
One of a pair of organs that make hormones and eggs for sexual reproduction.

**parametrium**
The fat and connective tissue surrounding the uterus. The parametrium helps connect the uterus to other tissues in the pelvis.

**pathologist**
An expert in testing cells and tissue to find disease.

**pelvic exam**
A physical exam of the external genitalia, vagina, cervix, uterus, fallopian tubes, and ovaries.

**pelvic exenteration**
A radical surgery used to treat cervical cancer that returns to the pelvis. The uterus (including the cervix), vagina, ovaries, and fallopian tubes are removed. The bladder, rectum, and/or anus may also be removed.

**pelvis**
The area of the body between the hip bones.
platinum-based chemotherapy
Treatment with two or more chemotherapy drugs and the main drug is made with platinum.

radiation oncologist
A doctor who is an expert in treating cancer with radiotherapy.

radical hysterectomy
Surgery to remove the uterus (including the cervix) and the top quarter or third of the vagina. The connective tissue and fat surrounding the cervix is also removed.

radiologist
A doctor who is an expert in interpreting imaging tests.

recurrence
The return of cancer after treatment. Also called a relapse.

reproductive system
The group of organs that work together for sexual reproduction. The female reproductive system includes the ovaries, fallopian tubes, uterus, cervix, and vagina.

squamocolumnar junction
The area where the endocervix and ectocervix meet. Also called the transformation zone. Most cervical cancers and pre-cancers start in the squamo-columnar junction.

squamous cell carcinoma
Cancer that starts in squamous cells lining the ectocervix. The most common type of cervical cancer.

supportive care
Treatment given to relieve the symptoms of a disease. Also called palliative care.

surgical menopause
The stopping of menstrual periods caused by surgery to remove the ovaries.

targeted therapy
Treatment with drugs that target a specific or unique feature of cancer cells.

trachelectomy
Surgery to remove the cervix. The upper part of the vagina and certain pelvic lymph nodes may also be removed.

uterus
The organ where a fetus grows and develops during pregnancy. Also called the womb.

vagina
The hollow, muscular tube through which babies are born. Also called the birth canal.
NCCN Contributors

This patient guide is based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer, Version 1.2024. It was adapted, reviewed, and published with help from the following people:

Dorothy A. Shead, MS  
Senior Director  
Patient Information Operations

Erin Vidić, MA  
Senior Medical Writer, Patient Information

Susan Kidney  
Senior Graphic Design Specialist

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer, Version 1.2024 were developed by the following NCCN Panel Members:

Nadeem R. Abu-Rustum, MD/Chair  
Memorial Sloan Kettering Cancer Center

Catheryn M. Yashar, MD/Vice Chair  
UC San Diego Moores Cancer Center

Rebecca Arend, MD  
O'Neal Comprehensive Cancer Center at UAB

Emma Barber, MD  
Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Stephanie Gaillard, MD, PhD  
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Robert Giuntoli II, MD  
Abramson Cancer Center at the University of Pennsylvania

Scott Glaser, MD, PhD  
City of Hope National Medical Center

Jordan Holmes, MD, MPH  
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Brooke E. Howitt, MD  
Stanford Cancer Institute

Jayanthi Lea, MD  
UT Southwestern Simmons Comprehensive Cancer Center

Gina Mantia-Smaldone  
Fox Chase Cancer Center

Andrea Mariani, MD  
Mayo Clinic Comprehensive Cancer Center

David Mutch, MD  
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Christa Nagel, MD  
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

*Larissa Nekhlyudov, MD, MPH  
Dana-Farber/Brigham and Women's Cancer Center

Mirna Podoll, MD  
Vanderbilt-Ingram Cancer Center

Kerry Rodabaugh MD  
Fred & Pamela Buffett Cancer Center

*Ritu Salani, MD, MBA  
UCLA Jonsson Comprehensive Cancer Center

John Schorge, MD  
St. Jude Children's Research Hospital/ The University of Tennessee Health Science Center

Jean Siedel, DO, MS  
University of Michigan Rogel Cancer Center

Rachel Sisodia, MD  
Mass General Cancer Center

*Pamela Soliman, MD, MPH  
The University of Texas MD Anderson Cancer Center

Stefanie Ueda, MD  
UCSF Helen Diller Family Comprehensive Cancer Center

Renata Urban, MD  
Fred Hutchinson Cancer Center

Stephanie L. Wethington, MD, MSc  
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

*Emily Wyse  
Patient Advocate

Kristine Zanotti, MD  
Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

NCCN Staff

Shaili Aggarwal, PhD  
Oncology Scientist/Medical Writer

Nicole McMillian, MS  
Senior Guidelines Coordinator

* Reviewed this patient guide. For disclosures, visit NCCN.org/disclosures.
NCCN Cancer Centers

Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania
800.789.7366 • pennmedicine.org/cancer

Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
UH Seidman Cancer Center
800.641.2422 • uhhospitals.org/services/cancer-services
CC Taussig Cancer Institute
866.223.8100 • my.clevelandclinic.org/departments/cancer
Case CCC
216.844.8797 • case.edu/cancer

City of Hope National Medical Center
Duarte, California
800.826.4673 • cityofhope.org

Dana-Farber/Brigham and Women’s Cancer Center | Mass General Cancer Center
Boston, Massachusetts
617.732.5500 • youhaveus.org
617.726.5130 • massgeneral.org/cancer-center

Duke Cancer Institute
Durham, North Carolina
888.275.3853 • dukecancerinstitute.org

Fox Chase Cancer Center
Philadelphia, Pennsylvania
888.369.2427 • foxchase.org

Fred & Pamela Buffett Cancer Center
Omaha, Nebraska
402.559.5800 • unmc.edu/cancercenter

Fred Hutchinson Cancer Center
Seattle, Washington
206.667.5000 • fredhutch.org

Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
800.824.2073 • healthcare.utah.edu/huntsmancancerinstitute

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
888.600.4822 • www.cancer.iu.edu

Mayo Clinic Comprehensive Cancer Center
Phoenix/Scottsdale, Arizona
Jacksonville, Florida
Rochester, Minnesota
480.301.8000 • Arizona
904.953.0853 • Florida
507.538.3270 • Minnesota
mayoclinic.org/cancercenter

Memorial Sloan Kettering Cancer Center
New York, New York
800.525.2225 • mskcc.org

Moffitt Cancer Center
Tampa, Florida
888.663.3488 • moffitt.org

O’Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama
800.822.0933 • uab.edu/onelancancercenter

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
866.587.4322 • cancer.northwestern.edu

Roswell Park Comprehensive Cancer Center
Buffalo, New York
877.275.7724 • roswellpark.org

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
St. Louis, Missouri
800.600.3606 • siteman.wustl.edu

St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
Memphis, Tennessee
866.278.5833 • sjude.org
901.448.5500 • ufhsc.edu

Stanford Cancer Institute
Stanford, California
877.668.7535 • cancer.stanford.edu

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Columbus, Ohio
800.293.5066 • cancer.osu.edu

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
410.955.8964
www.hopkinskimmelcancercenter.org

The UChicago Medicine Comprehensive Cancer Center
Chicago, Illinois
773.702.1000 • uchicagomedicine.org/cancer

The University of Texas MD Anderson Cancer Center
Houston, Texas
844.269.5922 • mdanderson.org

UC Davis Comprehensive Cancer Center
Sacramento, California
916.734.5959 • 800.770.9261
health.ucdavis.edu/cancer
UC San Diego Moores Cancer Center  
La Jolla, California  
858.822.6100 • cancer.ucsd.edu

UCLA Jonsson Comprehensive Cancer Center  
Los Angeles, California  
310.825.5268 • cancer.ucla.edu

UCSF Helen Diller Family Comprehensive Cancer Center  
San Francisco, California  
800.689.8273 • cancer.ucsf.edu

University of Colorado Cancer Center  
Aurora, Colorado  
720.848.0300 • coloradocancercenter.org

University of Michigan Rogel Cancer Center  
Ann Arbor, Michigan  
800.865.1125 • rogelcancercenter.org

University of Wisconsin Carbone Cancer Center  
Madison, Wisconsin  
608.265.1700 • uwhealth.org/cancer

UT Southwestern Simmons Comprehensive Cancer Center  
Dallas, Texas  
214.648.3111 • utsouthwestern.edu/simmons

Vanderbilt-Ingram Cancer Center  
Nashville, Tennessee  
877.936.8422 • vicc.org

Yale Cancer Center/Smilow Cancer Hospital  
New Haven, Connecticut  
855.4.SMILOW • yalecancercenter.org
## Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>biomarker</td>
<td>37, 48–49, 51–52</td>
</tr>
<tr>
<td>cervical dysplasia</td>
<td>7</td>
</tr>
<tr>
<td>chemoradiation</td>
<td>35, 37, 42–47, 55–56</td>
</tr>
<tr>
<td>clinical trial</td>
<td>28, 38–39, 48, 53, 56</td>
</tr>
<tr>
<td>fertility-sparing treatment</td>
<td>16, 32, 42–43</td>
</tr>
<tr>
<td>HER2</td>
<td>49, 52</td>
</tr>
<tr>
<td>human immunodeficiency virus (HIV)</td>
<td>8, 13</td>
</tr>
<tr>
<td>human papillomavirus (HPV)</td>
<td>5, 8</td>
</tr>
<tr>
<td>immunotherapy</td>
<td>37, 51–52</td>
</tr>
<tr>
<td>microsatellite instability (MSI)</td>
<td>49, 52</td>
</tr>
<tr>
<td>mismatch repair (MMR)</td>
<td>49, 52</td>
</tr>
<tr>
<td>NECC</td>
<td>9, 15, 47, 54–57</td>
</tr>
<tr>
<td>NTRK gene fusion</td>
<td>49, 52</td>
</tr>
<tr>
<td>ovarian transposition</td>
<td>16, 35</td>
</tr>
<tr>
<td>PD-L1</td>
<td>48–49, 51–52</td>
</tr>
<tr>
<td>premature menopause</td>
<td>33–35, 60</td>
</tr>
<tr>
<td>RET gene fusion</td>
<td>49, 52</td>
</tr>
<tr>
<td>sexual health</td>
<td>61–63</td>
</tr>
<tr>
<td>stereotactic body radiation therapy (SBRT)</td>
<td>34, 51</td>
</tr>
<tr>
<td>supportive care</td>
<td>28, 53, 56</td>
</tr>
<tr>
<td>surrogacy</td>
<td>16</td>
</tr>
<tr>
<td>survivorship</td>
<td>48, 58–63</td>
</tr>
<tr>
<td>tumor mutational burden (TMB)</td>
<td>49, 52</td>
</tr>
</tbody>
</table>
Cervical Cancer

2024

To support the NCCN Guidelines for Patients, visit

NCCNFoundation.org/Donate